Paul Tudor Jones Galecto, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$3.59 - $5.0 $194,219 - $270,500
-54,100 Closed
0 $0
Q2 2021

Aug 16, 2021
SELL
$4.63 - $8.0 $17,857 - $30,856
-3,857 Reduced 6.65%
54,100 $274,000
Q1 2021

May 17, 2021
SELL
$6.08 - $13.25 $39,264 - $85,568
-6,458 Reduced 10.03%
57,957 $352,000
Q4 2020

Feb 16, 2021
BUY
$12.51 - $16.84 $805,831 - $1.08 Million
64,415 New
64,415 $806,000

Others Institutions Holding GLTO

# of Institutions
1
Shares Held
21.2K
Call Options Held
0
Put Options Held
0
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $123M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email